TTNP : Summary for TITAN PHARMA INC - Yahoo Finance

U.S. Markets open in 2 hrs 2 mins

Titan Pharmaceuticals, Inc. (TTNP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.65-0.10 (-2.67%)
At close: 4:00PM EST
People also watch
VNDABDSIIMUCNAVBONCS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.75
Open3.75
Bid0.00 x
Ask3.75 x 200
Day's Range3.60 - 3.80
52 Week Range3.45 - 8.74
Volume115,267
Avg. Volume85,477
Market Cap77.38M
Beta1.65
PE Ratio (TTM)14.54
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire9 days ago

    Fast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech

    PRINCETON, N.J., Feb. 13, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals was named today by Fast Company as a Top 10 Most Innovative Company in Biotech in conjunction with its annual ranking of the world's 50 Most Innovative Companies for 2017. Braeburn's mission is to develop and deliver individualized, long-acting medicines to patients that suffer from serious, stigmatized neuropsychiatric disorders such as opioid addiction, chronic pain, and schizophrenia. In May 2016, Braeburn's Probuphine® received FDA approval and became the first buprenorphine implant for the long-term maintenance treatment of opioid addiction.

  • PR Newswirelast month

    Braeburn Pharmaceuticals' Probuphine® Implant Receives J-Code by Centers for Medicare & Medicaid Services

    PRINCETON, N.J., Jan. 13, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System ...

  • Titan Pharmaceuticals, Inc.: Strong price momentum but will it sustain?
    Capital Cube2 months ago

    Titan Pharmaceuticals, Inc.: Strong price momentum but will it sustain?

    Categories: Yahoo Finance Titan Pharmaceuticals, Inc. relative valuation is NEUTRAL and it has a fundamental analysis score of 58. Our analysis is based on comparing Titan Pharmaceuticals, Inc. with the following peers – Vanda Pharmaceuticals Inc., MediciNova, Inc., Celldex Therapeutics, Inc., Neuralstem, Inc., DURECT Corporation, Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, BioDelivery Sciences International, Inc., Johnson & ... Read more (Read more...)